We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.10 | -6.06% | 1.55 | 383,453 | 08:08:17 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.50 | 1.60 | 1.65 | 1.55 | 1.65 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 597k | -477k | -0.0035 | -4.43 | 2.1M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:22 | O | 500 | 1.60 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 21/11/2023 | 15:31 | UKREG | Physiomics PLC Result of AGM |
| 10/11/2023 | 15:14 | RNSNON | Physiomics PLC Business Update Presentation |
| 10/11/2023 | 10:26 | ALNC |  Physiomics gets UK government grant for oncology dosing tool project |
| 10/11/2023 | 07:00 | UKREG | Physiomics PLC Innovate UK grant award |
| 18/10/2023 | 06:00 | UKREG | Physiomics PLC Notice of AGM |
| 04/10/2023 | 06:00 | UKREG | Physiomics PLC Change of Registered Office |
| 03/10/2023 | 06:00 | RNSNON | Physiomics PLC Senior Management Announcement |
| 28/9/2023 | 11:12 | ALNC | Physiomics shares drop as annual loss widens; revenue falls |
| 28/9/2023 | 06:00 | UKREG | Physiomics PLC Annual Financial Report |
| 04/9/2023 | 10:21 | ALNC | Physiomics brings in chief operating officer; shares soar |
Physiomics (PYC) Share Charts1 Year Physiomics Chart |
|
1 Month Physiomics Chart |
Intraday Physiomics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 10/12/2023 | 07:12 | Physiomics - Cancer Treatment tech firm working with Merck + Oxford Uni | 11,422 |
| 17/6/2021 | 06:23 | PHYSIOMICS plc Virtual Tumor platform | 4,957 |
| 28/3/2021 | 21:05 | Physiomics PYC 2021 DISCUSSION (MODERATED) | 5 |
| 22/12/2020 | 11:36 | 3 Years ago today | 2 |
| 29/11/2020 | 14:53 | 3 Years ago today | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 10/12/2023 08:20 by Physiomics Daily Update Physiomics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker PYC. The last closing price for Physiomics was 1.65p.Physiomics currently has 135,472,478 shares in issue. The market capitalisation of Physiomics is £2,099,823. Physiomics has a price to earnings ratio (PE ratio) of -4.43. This morning PYC shares opened at 1.65p |
Posted at 05/12/2023 18:40 by davevt That's why pyc hardly gets any business. The big pharma do what pyc do in house, and for ALL types of drugs. Pyc only does dose prediction, and only for some cancer drugs. |
Posted at 07/10/2023 03:32 by porky9 @share14Personally, I'm starting to contribute less and less on any of these forums for the exact same reasons as you. I have been active on the Valirx board here and at LSE as my research notes are detailed and I can add value from an evaluation perspective but on all these boards, LSE is far far worse, they offer little value to evaluate and discuss with other investors. Over there they even request removal of posts that don't agree. The moderators then often just delete the entire threads for speed. Almost a total waste of time contributing. What's the point in that?? You cant discuss properly anything about the investee business because the installed cheerleaders just wont have any of it, they just want echo chambers and be comforted by others that think the same way and just there to ramp. Over on LSE earlier the cheerleader @Laura2022 is telling everyone PYC will get £6m from VAL. I mean i ask you, utterly ridiculous. But you are right that nobody will quantify anything i totally agree. Its just how it is, you have to Do your own research frankly, might as well keep it to yourself. @Davevt Thanks for your reply earlier. Everything you say is totally logical. From a quick check on google there are approximately 1,400 Biotech Businesses in the UK that carry our Drug R&D so that is Jim's market. As you say, perfectly feasible for a rep to visit each one in person over 20 years.... These businesses like PYC are clueless about sales and marketing, same over on Valirx, they will go and have a jolly at a trade show and consider that a good use of capital yet there are far more effective ways to reach that audience. My observation is that Jim is a reasonably hard working good guy that is constantly spinning plates, probably talking to the Biotech, working on the tenders through to taking an active part in the drug modeling itself and probably ordering more toilet roll for the bog on his way out the door at night. He is the knowledge. I have seen this so many times in other businesses. Also, In a Biotech financial squeeze, there is clearly less actual new business about and much business on hold so... It looked to me that prior to the drought, they were close to BE i was expecting that to happen and over the last two years the financial squeeze got worse pushing him further back. BUT i do think BE is achievable it's possible which then whist not revolutionary in its own right, at least puts investors minds at rest that they wont be on for yet another cash call. So I come back to the burning question, how do we add exponential growth to this business??. IF cash was available what would he do with it to grow this? Biostats modeling opens another consultancy area hence the new guy but more consultancy work whilst needed, is not the answer IMO. Its all labour intensive and the value of consultancy plays is minimal, like 1x Revenue so the current share price is probably right, 1p to 2p that's our lot. BUT what Jim does have at least is a good installed client base to work from. So to make this business more exciting, what are the expansion areas, clearly AI and product dev like Beyond Blood looks a winner, has anyone here any thoughts??? IF i could think of a fit here frankly i would go to Jim with it. What type of business can be acquired here to help materially advance this play? |
Posted at 04/10/2023 16:03 by share14 Happy to post about record revenues, strong pipelines, bla bla, then post a big loss and raise at 1p while claiming it's for expansion. Not exactly confidence inspiring is it.Why exactly do those shareholders on lse keep going on about PYC as if it's a great investment after those losses and the share price being decimated. Day in day out, same old thing for years, it's deranged behaviour. |
Posted at 03/10/2023 19:06 by davevt Laura is actually comedy gold. We had an rns today mentioning the new Biostatician....and it dropped the share price 8%.....and what does Laura do.? Keep posting the rns in the chat.. yes, I can only assume Laura wants to kill the share price, by reposting badly received rns's 🤣 |
Posted at 27/9/2023 13:00 by davevt '. Make no mistake pyc jumped 100% on a 150k contract so imagine what it will do when a multi million contract lands.'Not strictly true...only a few weeks ago the price was mid 2 and we had a 1p placing...so all it did was bring the price back right to where it was. If you think contracts this company gets raises the share price, you're in for a rude awakening. And pyc can't, or ever have ' multi million contract'...pyc dictate the price, and they charge around 35k for a pre clinical model and around 120 for a clinical model...because it takes so much longer. So the only way you could have a 'million' contract, is if by sheer chance, a drug company has 30 new drugs, all at the same time, for pyc to dose predict....ignoring the fact pyc only can work on about 4 to 5 projects a year. |
Posted at 22/9/2023 21:00 by davevt Yes, and ill repeat, pyc only charge 35k per drug, and hardly get any business because there are much larger, more advanced Biotech companies that do what pyc do, but much better, and faster, with more advanced tech...and also do it for all drugs, not only cancer drugs.Pyc has no skills for DDR. Even Merck, pycs main customer has teamed up with Artios instead to do all their DDR modelling for cancer drugs. 'Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response. Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets Artios to receive US$30 million in up-front and near-term payments, plus double-digit option fees and up to US$860 million total milestones per target Collaboration to leverage significant expertise and R&D resources of Merck KGaA, Darmstadt, Germany in the field of DNA Damage Response to identify and develop precision oncology medicines targeting nucleases ' Remember, pycs tech is very antiquated. Their virtual tumour software is twenty years old. You weren't even aware cruk was an existing client, admit it. |
Posted at 22/9/2023 19:33 by davevt It doesn't matter what CRUK have, pyc charge around £35k per drug they are asked to dose.CRUK have used pyc twice in the past 5 years, and neither of them, we know if pyc even charged them. Do the math. Why do you think pyc does such low revenues. It's only a 35 grand service. |
Posted at 10/9/2023 18:12 by davevt 'This is simply not true. The FDA have approved 25 new cancer drugs for commercial sale just this year alone.' I'm confused how you are arguing with me. You're literally arguing semantics of the word 'invented'....and then tell us only 25 drugs have succeeded...across ALL pharmas, across all of the USA...and for a drug to be approved 'this year' means it would have been first trialed years ago. If a drug isn't invented, it can't make it to a trial to require pyc to dose it. I'm not sure what you're trying to argue. Surely you don't think if pyc got 25 new clients on board, they all have a new cancer drug, every year? Pyc could get a client to agree to work with them...doesn't mean that client has anything in the pipeline at present for them. Once again, FDA is irrelevant to pyc, all of their customers are European / uk, so do not require FDA approval. Once again, if you look at pycs history, they manage to get a new customer on board every couple of years...but we also realise that previous customers we never hear from again. Currently it seems pyc have about 4 to 5 customers...but again, hard to tell...because they may have customers that simply haven't got anything oncology wise in the pipeline..so we don't see new work being undertaken. |
Posted at 08/9/2023 10:09 by davevt 'A biotech company approaches a computer modeller like PYC and says - "this is our early stage drug davevt1234X that comprises of compounds A, B and C. Tell us what is the optimal dosage for customer E that suffers from condition F". Computer modelling companies have a wealth of data and in the case of PYC 20 years worth. So unless the biotech company has discovered a new element that nobody has ever come across the computer model will be able to predict the outcome of the compounds on the patient.' If that was true, it wouldn't take them, as they have stated, on average 3 months to create a model. It works by the client having to give them lots of data, and if it doesn't get the desired results, they will use their findings to go back and improve the model. Those last two sentences I'm literally quoting from Jim as I remember him saying it in a video. this isn't my 'opinion'. This is why the pricing is cheap, as without the clients, pyc can't build a model. Remember, pycs virtual tumour system is over 2 decades old, it's antiquated in the grand scheme of things. And NO, it's not for 'customer e that suffers from f...that is only for personalized dosing. All of the contracts you see are for non personalized...just general optimized dosing. |
Posted at 08/9/2023 09:26 by davevt 'You've got this back to front. If they're feeding in data from a clinical trial to see if their computer comes up with the same results then that is not computer modelling, that's simply data analysis. The new guidance from the FCA is that they want to see results from computer modelling before they approve clinical trials.' Totally correct. Pyc do not do what you think they do. Think about it. Say a company comes to pyc and says 'hi, we want you to dose predict our new drug'...how the hell can pyc do anything without having data about how the drug works in the first place... Pyc will build a model of their prediction, give it to the client, and the client will run it along side their manual trial, and what the end result was, and who got the best one. If pycs prediction was top, they may get repeat work, if pycs model wasn't as good as the manual trial, pyc will then take the data and results from the trial to improve their model. The computers aren't psychic dude. It can't just model predict out of thin air. Maybe you're not aware, but the drugs pyc work on have 'already' been created and are known to work. All pyc is doing is trying to work out an 'optimum' dose. the drug company already has data on general dosing that works, and will give that data to pyc. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
